Nilotinib Associated With Increased Peripheral Artery Disease Rate in CML
Two studies found higher rates of peripheral artery occlusive disease in nilotinib-treated chronic myeloid leukemia patients than in imatinib-treated patients. (Source: Cancer Network)
Source: Cancer Network - May 13, 2013 Category: Cancer & Oncology Source Type: news
Gene Discovery May Offer Breakthrough for Rare Leukemia
Study found drug used for one condition also targets genes affecting different blood disorder
Source: HealthDay
Related MedlinePlus Pages: Chronic Myeloid Leukemia, Genes and Gene Therapy (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - May 9, 2013 Category: Consumer Health News Source Type: news
Common Mutations Found in Rare LeukemiasCommon Mutations Found in Rare Leukemias
More than 50% of patients with chronic neutrophilic leukemia and atypical chronic myeloid leukemia have active mutations in CSF3R, which could represent a target for therapy. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 8, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Are CML Drugs Priced Out of Reach?
A group of experts say that cancer drug prices, especially those for chronic myeloid leukemia, have skyrocketed, making patient treatment extremely difficult. (Source: Cancer Network)
Source: Cancer Network - May 2, 2013 Category: Cancer & Oncology Source Type: news
Patients' Health May Be Jeopardized By High Leukemia Treatment Costs
The increasing cost of treatments for chronic myeloid leukemia (CML) in the United States has reached unsustainably high levels and may be leaving many patients under - or untreated because they cannot afford care, according to a Blood Forum article supported by nearly 120 CML experts from more than 15 countries on five continents and published online in Blood, the Journal of the American Society of Hematology (ASH)... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 29, 2013 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news
Effective Leukemia Drugs Too Expensive, Desperate Patients Left Untreated
Eleven of the 12 drugs approved for treating chronic myeloid leukemia (CML) and some other cancers cost over $100,000 per year, leaving many desperate patients either untreated or under-treated because they simply cannot afford care, nearly 120 CML experts from over 15 countries reported today in the journal Blood. The authors describe the cost of chronic myeloid leukemia drug treatments as having reached "unsustainably high levels". Chronic myeloid leukemia is a highly curable disease, thanks to powerful, targeted therapies known as TKIs (tyrosine kinase inhibitors)... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 26, 2013 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news
Imatinib-Resistant Patients With Chronic Myeloid LeukemiaImatinib-Resistant Patients With Chronic Myeloid Leukemia
What's the best plan for patients with CML who don't respond to imatinib? Therapeutic Advances in Hematology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 26, 2013 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Soaring Prices Keep Leukemia Drugs from Patients, Experts Say
$100,000-a-year meds seen as obstacle to treatment
Source: HealthDay
Related MedlinePlus Pages: Chronic Myeloid Leukemia, Medicines (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - April 25, 2013 Category: Consumer Health News Source Type: news
Leading leukemia experts: High leukemia treatment costs may be harming patients
(American Society of Hematology) The increasing cost of treatments for chronic myeloid leukemia (CML) in the United States has reached unsustainably high levels and may be leaving many patients under- or untreated because they cannot afford care, according to a Blood Forum article supported by nearly 120 CML experts from more than 15 countries on five continents and published online today in Blood, the Journal of the American Society of Hematology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 25, 2013 Category: Global & Universal Source Type: news
Chronic Fatigue Limits Quality of Life in Imatinib-Treated CML Patients
A study of patients with chronic myeloid leukemia treated with imatinib found that chronic fatigue is the major factor that limits health-related quality of life. (Source: Cancer Network)
Source: Cancer Network - April 17, 2013 Category: Cancer & Oncology Source Type: news
Synribo (Omacetaxine Mepesuccinate) for Treating Chronic Myeloid Leukaemia
Synribo (Omacetaxine Mepesuccinate) is a subcutaneously injected drug developed by Teva Oncology, a division of Teva Pharmaceutical Industries, based in the US. The drug is indicated for the treatment of patients with chronic myelogenous leukaemia (C… (Source: Drug Development Technology)
Source: Drug Development Technology - April 8, 2013 Category: Pharmaceuticals Source Type: news
Iclusig (ponatinib) for the Treatment of Chronic Myeloid Leukaemia
Iclusig (ponatinib) is indicated for the treatment of chronic myeloid leukaemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ALL). The drug is discovered, developed and marketed by Ariad Pharmaceuticals. (Source: Drug Development Technology)
Source: Drug Development Technology - April 5, 2013 Category: Pharmaceuticals Source Type: news
CHMP recommends approval of Imatinib Actavis
Source: European Medicines Agency
Area: News
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the granting of a marketing authorisation for Imatinib Actavis for the treatment of:
. Paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment.
. Paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis.
...
Source: NeLM - News - February 25, 2013 Category: Drugs & Pharmacology Source Type: news
As CML Drugs Improve, Earlier Surrogate Outcome Markers Needed
As patients and physicians gain experience with a second generation of relatively effective therapies for chronic myeloid leukemia, there is increasing need to quickly understand who will fare best with these drugs. (Source: Cancer Network)
Source: Cancer Network - February 20, 2013 Category: Cancer & Oncology Source Type: news
Targeting Leukemic Stem Cells in Marrow Could Stave Off TKI Resistance
New research suggests that a novel, investigative drug could help alleviate some of the resistance to tyrosine kinase inhibitor treatment seen in chronic myeloid leukemia (CML). The drug, a pan-BCL2 inhibitor called sabutoclax, could sensitize malignant leukemic stem cells in the bone marrow niche to TKI treatment. (Source: Cancer Network)
Source: Cancer Network - February 19, 2013 Category: Cancer & Oncology Source Type: news
